CDK2 and prostate carcinoma: In addition, CDK-2 affects hormone-dependent cancers by phosphorylating the receptors of androgen, estrogen, and progesterone and increasing their transcriptional activity and CDK-2 inhibition has been reported to prevent the progression of prostate cancer and breast cancer [48, 49].